grant
CD28-KITv CAR T cells with PD-1 dominant negative receptor
Organization SLOAN-KETTERING INST CAN RESEARCHLocation NEW YORK, UNITED STATESPosted 1 Mar 2024Deadline 28 Feb 2029
NIHUS FederalResearch GrantFY2026AddressAntigen TargetingAntigensB7-H1Behavior Conditioning TherapyBehavior ModificationBehavior TherapyBehavior TreatmentBehavioral Conditioning TherapyBehavioral ModificationBehavioral TherapyBehavioral TreatmentBone-Derived Transforming Growth FactorBronchopulmonary SequestrationC-KIT MutationCAR T cell therapyCAR T cellsCAR T therapyCAR modified T cellsCAR-TCAR-TsCD117 MutationCD274CD28CD28 geneCancersCell BodyCell Communication and SignalingCell FunctionCell PhysiologyCell ProcessCell SignalingCell TherapyCellsCellular FunctionCellular PhysiologyCellular ProcessCheckpoint inhibitorChemotactic CytokinesChemotaxisClinicalClinical TrialsConditioning TherapyDNA mutationDominant Negative ReceptorDoseEnvironmentFoundationsGenerationsGenetic ChangeGenetic defectGenetic mutationHematologic CancerHematologic MalignanciesHematologic NeoplasmsHematological MalignanciesHematological NeoplasmsHematological TumorHematopoietic CancerHomologous Chemotactic CytokinesIFN-GammaIFN-gIFN-γIFNGIFNγIND FilingIND applicationIND packageIND submissionImageImmune InterferonImmune checkpoint inhibitorImmune responseImmunomodulationImmunosuppressantsImmunosuppressionImmunosuppression EffectImmunosuppressive AgentsImmunosuppressive EffectImmunosuppressive drugImmunosuppressive treatmentInfiltrationInfusionInfusion proceduresIntercrinesInterferon GammaInterferon Type IIIntracellular Communication and SignalingInvestigational New Drug ApplicationLiteratureLow Dose RadiationLytotoxicityMacrophageMalignant Hematologic NeoplasmMalignant Mesothelioma of the PleuraMalignant NeoplasmsMalignant Pleural EffusionMalignant Pleural MesotheliomaMalignant Pleural NeoplasmMalignant Pleural TumorMalignant TumorMediatingMilk Growth FactorModelingMutationMφPD 1PD-1PD-1 antibodyPD-L1PD1PD1 antibodyPDL-1Pathway interactionsPatientsPhasePhase 1/2 trialPhase I StudyPhase I/II TrialPlatelet Transforming Growth FactorPleura CancerPleural CancerPreclinical dataProcessProgrammed Cell Death 1 Ligand 1Programmed Death Ligand 1ProliferatingPulmonary SequestrationRadiation therapyRadiotherapeuticsRadiotherapyRegimenResistanceSIS cytokinesSafetySignal TransductionSignal Transduction SystemsSignalingSolid NeoplasmSolid TumorSoluble Mpf/Mesothelin-Related ProteinStressSubcellular ProcessT cell receptor based immunotherapyT cell receptor cellular immunotherapyT cell receptor engineered therapyT cell receptor immunotherapyT cells for CART-Cell ProliferationT-Cell Receptor TherapyT-Cell Receptor TreatmentT-Cell Receptor based TherapyT-Cell Receptor based TreatmentT-CellsT-LymphocyteT44TCR T cell immunotherapyTCR T cell therapyTCR TherapyTCR based T cell immunotherapyTCR based TherapyTCR based immune therapyTCR based immunotherapyTCR based treatmentTCR immunotherapyTGF BTGF-betaTGF-βTGFbetaTGFβTNBCToxic effectToxicitiesTransforming Growth Factor betaTransforming Growth Factor-Beta Family GeneTranslatingTumor CellTumor PromotionaPD-1aPD1anti programmed cell death 1anti-PD-1anti-PD-1 Abanti-PD-1 antibodiesanti-PD-1 monoclonal antibodiesanti-PD1anti-PD1 Abanti-PD1 antibodiesanti-PD1 monoclonal antibodiesanti-programmed cell death protein 1anti-programmed cell death protein 1 antibodiesanti-programmed death-1 antibodyantiPD-1behavior interventionbehavioral interventionbiological signal transductioncancer microenvironmentcell based interventioncell mediated interventioncell mediated therapiescell-based therapeuticcell-based therapycellular therapeuticcellular therapycheck point blockadecheckpoint blockadechemoattractant cytokinechemokinechimeric antigen T cell receptorchimeric antigen receptorchimeric antigen receptor (CAR) T cell therapychimeric antigen receptor (CAR) T cellschimeric antigen receptor Tchimeric antigen receptor T cell therapychimeric antigen receptor T cellschimeric antigen receptor T therapychimeric antigen receptor fusion protein T-cellschimeric antigen receptor modified T cellscytotoxicityexhaustexhaustiongenome mutationhost responseimagingimmune check point blockadeimmune check point inhibitorimmune checkpoint blockadeimmune modulationimmune regulationimmune suppressionimmune suppressive activityimmune suppressive agentimmune suppressive functionimmune suppressorimmune system responseimmunogenimmunologic reactivity controlimmunomodulatoryimmunoregulationimmunoregulatoryimmunoresponseimmunosuppressive activityimmunosuppressive functionimmunosuppressive responseimmunosuppressive substanceimmunosuppressorinfusionskinase inhibitorlFN-Gammamalignancymalignant pleura neoplasmmalignant pleura tumormesothelinneoplasm/cancerneoplastic cellnext generationoverexpressoverexpressionpathwayperipheral bloodphase 1 studypreclinical findingspreclinical informationpreconditioningprogrammed cell death 1programmed cell death ligand 1programmed cell death protein 1programmed cell death protein ligand 1programmed death 1protein death-ligand 1radiation treatmentresistantresponseresponse biomarkerresponse markerssle2successsystemic lupus erythematosus susceptibility 2thymus derived lymphocytetranslation strategytranslational approachtranslational strategytreatment with radiationtriple-negative breast cancertriple-negative invasive breast carcinomatumortumor microenvironmentαPD-1αPD1
Description preview
PROJECT ABSTRACT
The success of chimeric antigen receptor (CAR) T-cell therapy in solid tumors requires antigen targets with no
on-target, off-tumor toxicity, effective tumor infiltration, cytotoxicity and proliferation in an immunosuppressive
environment, and revival of antigen stress-induced exhausted CAR T cells. We translated CD28-costimulated…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click